Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ZYMEWORKS INC.

(ZYME)
  Report
Real-time Estimate Cboe BZX  -  02:11:29 2023-01-30 pm EST
9.240 USD   -3.55%
01/25Zymeworks Announces Participation in Upcoming Investor Conferences
BU
01/20Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
AQ
01/20SVB Securities Raises Price Target on Zymeworks to $10 From $8, Maintains Market Perform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société ZYMEWORKS INC.
01/25Zymeworks Announces Participation in Upcoming Investor Conferences
BU
01/20Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phas..
AQ
01/04Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
BU
2022Jazz Pharmaceuticals And Zymeworks Announce Jazz Has Confirmed Opt-In And Advances Part..
AQ
2022Zymeworks Announces Participation in Upcoming Investor Conference
BU
2022Zymeworks Announces Positive Topline Data in The Pivotal HERIZON-BTC-01 Trial Of Zanida..
AQ
2022Zymeworks Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2022Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical..
BU
2022Zymeworks Inc - New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cance..
AQ
2022New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Toda..
BU
2022Zymeworks to Transfer Stock Listing to Nasdaq
BU
2022Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab Lice..
BU
2022Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Recepto..
AQ
2022Zymeworks Announces Participation in Upcoming Investor Conference
BU
2022Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Recepto..
BU
2022Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results
BU
2022Zymeworks Bc Inc. : Entry into a Material Definitive Agreement, Termination of a Material ..
AQ
2022Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and..
BU
2022Zymeworks Bc Inc. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, ..
AQ
2022Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab
BU
2022Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and ..
AQ
2022Zymeworks to Host Third Quarter Results Conference Call
BU
2022Zymeworks Bc Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other..
AQ
2022Zymeworks Completes Plan to Become Delaware Corporation
BU
2022Zymeworks Inc. : Entry into a Material Definitive Agreement, Termination of a Material Def..
AQ
2022Zymeworks : REPORT OF VOTING RESULTS - Form 8-K
PU
2022Zymeworks Inc. : Submission of Matters to a Vote of Security Holders, Regulation FD Disclo..
AQ
2022Zymeworks Announces Results of Special Meeting
AQ
2022Zymeworks Announces Results of Special Meeting
BU
2022Zymeworks Reminds Shareholders to Vote FOR its Redomicile
BU
2022Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research a..
AQ
2022Zymeworks Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2022Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &..
BU
2022Zymeworks Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2022Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile
BU
2022Zymeworks : Shareholder Director Nominations - Form 8-K
PU
2022Zymeworks Inc. : Other Events (form 8-K)
AQ
2022Zymeworks Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2022Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR ..
BU
2022Zymeworks Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2022Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at..
BU
2022Zymeworks Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2022Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve ..
BU
2022Zymeworks Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2022Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin..
AQ
2022Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin..
BU
2022Zymeworks Inc. : Other Events (form 8-K)
AQ
2022Zymeworks Inc. : Unregistered Sale of Equity Securities (form 8-K)
AQ
2022Zymeworks Inc. : Entry into a Material Definitive Agreement, Financial Statements and Exhi..
AQ
2022Zymeworks Inc. : Other Events (form 8-K)
AQ
2022Zymeworks : FORM 51-102F3 - Form 8-K
PU
2022Zymeworks Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure, Fina..
AQ
2022Zymeworks : Provides Corporate Update andReports Second Quarter 2022 Financial Results - F..
PU
2022Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
BU
2022ZYMEWORKS INC. Management's Discussion and Analysis of Financial Condition and Results..
AQ
2022Zymeworks : Announces Participation in Upcoming Investor Conferences - Form 8-K
PU
2022Zymeworks Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2022Zymeworks Announces Participation in Upcoming Investor Conferences
BU
2022Zymeworks : Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodoti..
PU
2022Zymeworks Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2022Zymeworks Reports Inducement Grant To New Chief Scientific Officer
AQ
2022Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodot..
BU
2022Zymeworks : Reports Inducement Grant to New Chief Scientific Officer - Form 8-K
PU
2022Zymeworks Reports Inducement Grant to New Chief Scientific Officer
BU
2022Zymeworks : to Host Second Quarter Results Conference Call - Form 8-K
PU
2022Zymeworks Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2022Zymeworks to Host Second Quarter Results Conference Call
BU
2022Zymeworks Announces Plan To Become A Delaware Corporation
AQ
2022Zymeworks Inc. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Oth..
AQ
2022Zymeworks Announces Plan to Become a Delaware Corporation
BU
2022Zymeworks : Appoints Dr. Paul Moore as Chief Scientific Officer - Form 8-K
PU
2022Zymeworks Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2022Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
BU
2022Zymeworks : Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to ..
PU
2022Zymeworks Inc. : Entry into a Material Definitive Agreement, Material Modification to Righ..
AQ
1  2  3  4  5Next